Mylan’s EpiPen Pricing Explanation To Senate ‘Incomplete,’ According To Judiciary Chairman
Sen. Chuck Grassley (R-Iowa) says he is not satisfied with the drugmaker's seven-page letter and says further congressional action is possible. In other industry news, pharmaceutical companies keep the biotech outlook bright.